Share on StockTwits

Equities researchers at Gabelli started coverage on shares of Cempra Holdings (NASDAQ:CEMP) in a research report issued on Friday. The firm set a “buy” rating on the stock.

Shares of Cempra Holdings (NASDAQ:CEMP) opened at 10.43 on Friday. Cempra Holdings has a 52-week low of $6.95 and a 52-week high of $15.39. The stock’s 50-day moving average is $9.23 and its 200-day moving average is $11.30. The company’s market cap is $346.3 million.

Cempra Holdings (NASDAQ:CEMP) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.48) by $0.03. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.10 million. Analysts expect that Cempra Holdings will post $-2.22 EPS for the current fiscal year.

Separately, analysts at Barclays initiated coverage on shares of Cempra Holdings in a research note on Tuesday, April 8th. They set an “equal weight” rating and a $13.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.63.

Cempra, Inc, formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.